• Operating expenses in line with the Company’s development
• Solid cash position of €31.2m at December 31, 2016
Paris, February 14, 2017 - 7:30 am CET
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces its annual results for the year to December 31, 2016 [1].
For full access, please click here.
